Enrique Grande

Summary

Publications

  1. doi request reprint Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 12:481-92. 2010
  2. doi request reprint Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:477-9. 2011
  3. doi request reprint New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies
    Enrique Grande
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Expert Rev Anticancer Ther 12:457-67. 2012
  4. doi request reprint Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Universitario Ramón y Cajal de Madrid, Madrid, Spain
    Cancer Metastasis Rev 31:47-53. 2012
  5. doi request reprint Targeting oncogenic ALK: a promising strategy for cancer treatment
    Enrique Grande
    Gastrointestinal and Early Drug Development Unit, Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Mol Cancer Ther 10:569-79. 2011
  6. doi request reprint Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma
    María Angeles Vaz
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:817-21. 2011
  7. doi request reprint Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma
    Rosario Garcia-Campelo
    Medical Oncology Service, University Hospital Complex, A Coruna, Spain
    Anticancer Drugs 21:S13-5. 2010
  8. doi request reprint The potential role of sunitinib in gastrointestinal cancers other than GIST
    Cristina Gravalos
    Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda de Andalucía s n Km 5 400, 28041 Madrid, Spain
    Crit Rev Oncol Hematol 76:36-43. 2010
  9. doi request reprint Sorafenib in metastatic thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Endocr Relat Cancer 19:209-16. 2012
  10. doi request reprint Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients
    Daniel Castellano
    Medical Oncology Department, 12 de Octubre University Hospital, Av Córdoba Km 5, 4, PO Box 28041, Madrid, Spain
    Expert Opin Pharmacother 12:2433-9. 2011

Detail Information

Publications12

  1. doi request reprint Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 12:481-92. 2010
    ..In fact, mTOR inhibitors have shown activity in uncontrolled trials, and large, randomised trial results will be available shortly. In this article, we summarise the most recent available data on medical therapy for GEPNETs...
  2. doi request reprint Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:477-9. 2011
    ..To our knowledge, this is the first reported case of treatment with sunitinib in a patient with PNET in response to Choi criteria...
  3. doi request reprint New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies
    Enrique Grande
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Expert Rev Anticancer Ther 12:457-67. 2012
    ..In this article we review the rationale for the use of novel ubiquitin-proteasome system inhibitors in gastrointestinal malignancies...
  4. doi request reprint Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Universitario Ramón y Cajal de Madrid, Madrid, Spain
    Cancer Metastasis Rev 31:47-53. 2012
    ..New therapeutic approaches in the field of CSCs seem to have a clear role in the treatment of medulloblastomas and basal cell carcinomas, but their future value in other solid tumor types including NETs remains unclear...
  5. doi request reprint Targeting oncogenic ALK: a promising strategy for cancer treatment
    Enrique Grande
    Gastrointestinal and Early Drug Development Unit, Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Mol Cancer Ther 10:569-79. 2011
    ....
  6. doi request reprint Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma
    María Angeles Vaz
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:817-21. 2011
    ..Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective...
  7. doi request reprint Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma
    Rosario Garcia-Campelo
    Medical Oncology Service, University Hospital Complex, A Coruna, Spain
    Anticancer Drugs 21:S13-5. 2010
    ..The whole-body CT did not reveal any other abnormality except for the known lung nodes. PET scan six months after treatment confirmed complete gastric response...
  8. doi request reprint The potential role of sunitinib in gastrointestinal cancers other than GIST
    Cristina Gravalos
    Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda de Andalucía s n Km 5 400, 28041 Madrid, Spain
    Crit Rev Oncol Hematol 76:36-43. 2010
    ....
  9. doi request reprint Sorafenib in metastatic thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Endocr Relat Cancer 19:209-16. 2012
    ..033). In this retrospective trial, sorafenib showed antitumor efficacy in all histological subtypes of thyroid cancer, warranting further development in this setting...
  10. doi request reprint Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients
    Daniel Castellano
    Medical Oncology Department, 12 de Octubre University Hospital, Av Córdoba Km 5, 4, PO Box 28041, Madrid, Spain
    Expert Opin Pharmacother 12:2433-9. 2011
    ..Sunitinib has shown activity in CRPC and at the time of this analysis there was no standard therapy for docetaxel-refractory CRPC...
  11. ncbi request reprint Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
    Luis Paz-Ares
    Oncology Department, Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 10:831-9. 2008
    ..The purpose of this study is to assess the cost-effectiveness of sunitinib vs. best supportive care (BSC) in GIST as a second- line treatment, from the perspective of the Spanish National Health System...
  12. pmc Thyroid cancer: molecular aspects and new therapeutic strategies
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
    J Thyroid Res 2012:847108. 2012
    ..The correct molecular characterization of patients with thyroid cancer is thought to be a key aspect for the future clinical management of these patients...